Literature DB >> 15285708

MVA as a vector for vaccines against HIV-1.

Eung-Jun Im1, Tomás Hanke.   

Abstract

A vaccine against HIV Type 1 (HIV-1) is urgently needed. Modified vaccinia virus Ankara is an attenuated smallpox vaccine which can be adapted to express HIV-1 antigens. In this review, we discuss the features which make modified vaccinia virus Ankara an attractive vector for genetic vaccines and have put it, together with several other recombinant viral vectors, at the forefront of HIV-1 vaccine development. Many candidate vaccines including those vectored by modified vaccinia virus Ankara are now entering human trials, the results of which will become available in the coming years.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15285708     DOI： 10.1586/14760584.3.4.s89

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  8 in total

1.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

2.  Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Authors:  Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong Y Tsang
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

Review 3.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

4.  Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Authors:  Richard Hopkins; Anne Bridgeman; Joan Joseph; Sarah C Gilbert; Helen McShane; Tomáš Hanke
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

5.  Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.

Authors:  Nicola Ternette; Peter D Block; Álvaro Sánchez-Bernabéu; Nicola Borthwick; Elisa Pappalardo; Sultan Abdul-Jawad; Beatrice Ondondo; Philip D Charles; Lucy Dorrell; Benedikt M Kessler; Tomáš Hanke
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

6.  A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.

Authors:  Muhammed O Afolabi; Jorjoh Ndure; Abdoulie Drammeh; Fatoumatta Darboe; Shams-Rony Mehedi; Sarah L Rowland-Jones; Nicola Borthwick; Antony Black; Gwen Ambler; Grace C John-Stewart; Marie Reilly; Tomáš Hanke; Katie L Flanagan
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

Review 7.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

8.  Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

Authors:  Emma-Jo Hayton; Annie Rose; Umar Ibrahimsa; Mariarosaria Del Sorbo; Stefania Capone; Alison Crook; Antony P Black; Lucy Dorrell; Tomáš Hanke
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.